ZIM
LCTX icon

Zacks Investment Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Zacks Investment Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.1K Buy
+42,084
New +$58.2K ﹤0.01% 717
2025
Q2 		– Sell
-45,692
Closed -$20.6K – 741
2025
Q1 		$20.6K Buy
+45,692
New +$26.8K ﹤0.01% 649
2019
Q3 		– Sell
-77,609
Closed -$85K – 552
2019
Q2 		$85K Buy
+77,609
New +$89.4K ﹤0.01% 518

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Zacks Investment Management's LCTX Position: Q2 2026 in Review

Zacks Investment Management opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 42,084 shares worth $55.1K. The stake represents ﹤0.01% of the portfolio and ranks #717 among its holdings. This is a return to the name: Zacks Investment Management previously reported a position in LCTX as recently as Q1 2025.

Zacks Investment Management first reported a position in LCTX in Q2 2019 and has held it in 3 quarters since. The position peaked at $85K in Q2 2019. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Zacks Investment Management held 42,084 shares of Lineage Cell Therapeutics worth $55.1K as of Q2 2026.
  • Lineage Cell Therapeutics was a new Zacks Investment Management position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Zacks Investment Management's portfolio in Q2 2026, its #717 holding.
  • Zacks Investment Management first reported a position in Lineage Cell Therapeutics in Q2 2019 and has held it in 3 quarters since.
  • Zacks Investment Management's Lineage Cell Therapeutics position peaked at $85K in Q2 2019.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Zacks Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.